發(fā)布時間：2018-04-15 00:34

  本文選題：新興醫(yī)藥市場 + 專利懸崖��； 參考：《首都經(jīng)濟(jì)貿(mào)易大學(xué)》2013年碩士論文

【摘要】：合適的企業(yè)戰(zhàn)略能引領(lǐng)公司良性發(fā)展，能使企業(yè)在市場競爭中獲勝，選擇正確的產(chǎn)品開發(fā)戰(zhàn)略對一個制藥企業(yè)來說有戰(zhàn)略意義。國際醫(yī)藥市場穩(wěn)步發(fā)展，尤其如今在包括中國在內(nèi)的新興醫(yī)藥市場中，醫(yī)藥支出快速發(fā)展，而且隨著大制藥企業(yè)重磅產(chǎn)品專利到期帶來的市場缺口，給制藥企業(yè)創(chuàng)造了巨大商機(jī)。全球開發(fā)創(chuàng)新藥的難度越來越大，研發(fā)費用越來越高，國際大型制藥企業(yè)也很難承擔(dān)，，很多企業(yè)紛紛走向仿制藥物。在中國政府鼓勵創(chuàng)新、新醫(yī)改以及藥品降價等宏觀環(huán)境背景下，本文通過分析華潤雙鶴藥業(yè)的發(fā)展歷史、現(xiàn)狀和公司的戰(zhàn)略規(guī)劃，提出仿創(chuàng)結(jié)合，仿中有創(chuàng)，以仿制為主導(dǎo)的產(chǎn)品開發(fā)戰(zhàn)略。在產(chǎn)品選擇上，要做到人無我有--唯一性、人有我新--新穎性、人新我優(yōu)--優(yōu)越性，要從包含戰(zhàn)略匹配度、研發(fā)時機(jī)、學(xué)術(shù)機(jī)理、技術(shù)門檻、被仿公司、知識產(chǎn)權(quán)保護(hù)以及投產(chǎn)可行性等七個因素在內(nèi)的生產(chǎn)和研發(fā)維度以及包含市場保護(hù)、學(xué)術(shù)價值、競爭程度、市場容量、價值鏈評估和內(nèi)部資源匹配等六個因素在內(nèi)的市場維度進(jìn)行品種選擇評估體系，按照評分結(jié)果將產(chǎn)品畫入四個象限來確定是否可以開發(fā)該品種。
[Abstract]:The appropriate enterprise strategy can lead to the benign development of the company and make the enterprise win in the market competition. It is of strategic significance for a pharmaceutical enterprise to choose the correct product development strategy.The international pharmaceutical market has developed steadily, especially in the emerging pharmaceutical markets, including China, where pharmaceutical expenditure has developed rapidly, and with the market gap brought about by the expiration of patents on the blockbuster products of large pharmaceutical enterprises,It creates huge business opportunities for pharmaceutical companies.The global development of innovative drugs is becoming more and more difficult, R & D costs are increasing, international large pharmaceutical companies are also very difficult to afford, many companies have moved towards generic drugs.Against the background of the Chinese government encouraging innovation, new medical reform and drug price reduction, this paper analyzes the development history, current situation and strategic planning of China Resources Shuanghe Pharmaceutical Industry, and proposes a combination of imitation and creation.Product development strategy based on imitation.In the selection of products, we should make sure that people have-uniqueness without self, people with new novelty, people with new advantages and advantages. They should include strategic matching degree, research and development opportunity, academic mechanism, technical threshold, and be imitated by the company.The dimensions of production and R & D, including the protection of intellectual property rights and the feasibility of putting into production, including market protection, academic value, degree of competition, market capacity,In the market dimension of value chain evaluation and internal resource matching, a variety selection evaluation system is carried out. According to the evaluation results, the product is drawn into four quadrants to determine whether the product can be developed.
【學(xué)位授予單位】：首都經(jīng)濟(jì)貿(mào)易大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：F273.2;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 謝輝,卞鷹,江濱;日本新藥研發(fā)策略及對中國的啟示[J];中國創(chuàng)業(yè)投資與高科技;2005年07期

2 朱寶鳳;我國創(chuàng)新藥研發(fā)現(xiàn)狀與對策[J];高科技與產(chǎn)業(yè)化;2005年07期

3 杜丹麗;王發(fā)銀;;企業(yè)戰(zhàn)略管理思想的發(fā)展歷程及其新視角[J];管理科學(xué)文摘;2006年10期

4 劉彥明;;專利到期藥物的仿制策略與國際認(rèn)證途徑分析[J];中國發(fā)明與專利;2011年10期

5 陳曉潔;王瑋;;我國新藥研發(fā)和發(fā)展的現(xiàn)狀[J];海峽藥學(xué);2009年01期

6 張偉;;我國醫(yī)藥產(chǎn)業(yè)技術(shù)創(chuàng)新能力研究[J];科技信息(學(xué)術(shù)研究);2008年21期

7 張廣洲;王鳳山;;對我國新藥研發(fā)現(xiàn)狀的幾點思考[J];齊魯藥事;2007年01期

8 戴浩森;;2006年國內(nèi)外醫(yī)藥行業(yè)發(fā)展現(xiàn)狀分析[J];中國醫(yī)藥技術(shù)經(jīng)濟(jì)與管理;2007年01期

9 徐玉玲;凌婭;肖偉;王振中;劉濤;;淺談我國新藥研發(fā)的關(guān)鍵點[J];藥學(xué)與臨床研究;2011年01期

10 張黎黎;林蕓鋒;田玲;;全球新藥研發(fā)現(xiàn)狀與部分國家研發(fā)策略簡析[J];醫(yī)學(xué)研究雜志;2009年12期

本文編號：1751749